Compare · MRK vs PRTA
MRK vs PRTA
Side-by-side comparison of Merck & Company Inc. (MRK) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $314.90B, about 694.6x PRTA ($453.4M).
- Over the past year, MRK is up 60.7% and PRTA is up 37.6% - MRK leads by 23.1 points.
- MRK has hit the wire 8 times in the past 4 weeks while PRTA has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 22 for PRTA).
- Company
- Merck & Company Inc.
- Prothena Corporation plc
- Price
- $127.48-0.14%
- $8.65+2.06%
- Market cap
- $314.90B
- $453.4M
- 1M return
- +10.60%
- +4.59%
- 1Y return
- +60.72%
- +37.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 22
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest MRK
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.
Latest PRTA
- Large owner Scully William P bought $157,990 worth of Ordinary Shares (20,000 units at $7.90), increasing direct ownership by 3% to 756,000 units (SEC Form 4)
- Large owner Scully William P gifted 325,000 units of Ordinary Shares, decreasing direct ownership by 31% to 736,000 units (SEC Form 4)
- Large owner Scully William P bought $1,021,225 worth of Ordinary Shares (125,000 units at $8.17), increasing direct ownership by 13% to 1,061,000 units (SEC Form 4)
- New insider Isaacs Michael John claimed ownership of 48,825 units of Ordinary Shares (SEC Form 3)
- SEC Form 144 filed by Prothena Corporation plc
- Large owner Scully William P bought $465,295 worth of Ordinary Shares (50,000 units at $9.31), increasing direct ownership by 6% to 936,000 units (SEC Form 4)
- Large owner Scully William P bought $471,300 worth of Ordinary Shares (50,000 units at $9.43), increasing direct ownership by 6% to 886,000 units (SEC Form 4)
- Large owner Scully William P bought $981,300 worth of Ordinary Shares (100,000 units at $9.81), increasing direct ownership by 14% to 836,000 units (SEC Form 4)
- SEC Form 4 filed by Director Welch Daniel G
- SEC Form 4 filed by Director Selkoe Dennis J.